Trial Profile
Phase II Study of Maintenance Anti-PD-L1 Treatment With Atezolizumab After Chemo-radiotherapy for Muscle-infiltrating Bladder Cancer Patients Not Eligible for Radical Cystectomy: Bladder Sparing
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Nov 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Bladder cancer; Squamous cell cancer; Urogenital cancer
- Focus Therapeutic Use
- Acronyms BladderSpar
- 09 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 05 Jul 2022 Planned End Date changed from 15 Feb 2027 to 15 Feb 2029.
- 05 Jul 2022 Planned primary completion date changed from 15 Feb 2023 to 15 Jun 2025.